mebendazole has been researched along with dronedarone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ahmed, MS; Boys, IN; DeBerardinis, RJ; Eitson, JL; Fan, W; Farag, AB; Kim, SY; Lemoff, A; Mar, K; McDougal, MB; Menendez-Montes, I; Nguyen, NUN; Ohlson, MB; Ortiz, F; Sadek, HA; Schoggins, JW; Solmonson, A; Thet, S; Wang, P; Williams, NS | 1 |
1 review(s) available for mebendazole and dronedarone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for mebendazole and dronedarone
| Article | Year |
|---|---|
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.
Topics: Antiviral Agents; Atovaquone; COVID-19; Dihydroorotate Dehydrogenase; Dronedarone; Drug Repositioning; Humans; Mebendazole; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Protease Inhibitors; Purines; SARS-CoV-2 | 2023 |